tadalafil has been researched along with Hyperglycemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L | 1 |
| Angielski, S; Audzeyenka, I; Kulesza, T; Myślińska, D; Piwkowska, A; Rachubik, P; Rogacka, D; Szrejder, M | 1 |
| Jansson, PA; Lönnroth, P; Sandqvist, M; Strindberg, L | 1 |
1 review(s) available for tadalafil and Hyperglycemia
| Article | Year |
|---|---|
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hydroxychloroquine; Hyperglycemia; Insulin Resistance; Male; Mice; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2023 |
1 trial(s) available for tadalafil and Hyperglycemia
| Article | Year |
|---|---|
Decreased permeability surface area for glucose in obese women with postprandial hyperglycemia: no effect of phosphodiesterase-5 (PDE-5) inhibition.
Topics: Aged; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Glucose; Humans; Hyperglycemia; Middle Aged; Obesity; Permeability; Phosphodiesterase Inhibitors; Postprandial Period; Tadalafil; Treatment Outcome | 2013 |
1 other study(ies) available for tadalafil and Hyperglycemia
| Article | Year |
|---|---|
Inhibition of phosphodiesterase 5A by tadalafil improves SIRT1 expression and activity in insulin-resistant podocytes.
Topics: AMP-Activated Protein Kinases; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetic Nephropathies; Glucose; Humans; Hyperglycemia; Insulin; Insulin Resistance; Podocytes; Sirtuin 1; Tadalafil | 2023 |